Acelyrin, Inc. (SLRN)
- Previous Close
4.2400 - Open
4.2500 - Bid 4.2200 x 300
- Ask 4.2500 x 400
- Day's Range
4.1900 - 4.3400 - 52 Week Range
4.1800 - 29.8800 - Volume
654,229 - Avg. Volume
1,229,139 - Market Cap (intraday)
419.391M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-5.4300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.17
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
www.acelyrin.comRecent News: SLRN
Performance Overview: SLRN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SLRN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SLRN
Valuation Measures
Market Cap
419.39M
Enterprise Value
-300.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.64
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.71
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.93%
Return on Equity (ttm)
-80.34%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-381.64M
Diluted EPS (ttm)
-5.4300
Balance Sheet and Cash Flow
Total Cash (mrq)
721.33M
Total Debt/Equity (mrq)
0.22%
Levered Free Cash Flow (ttm)
-89.95M